Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Intranasal Foralumab in Alzheimer's disease. The expected timing is based on the latest available company guidance and may change.
IND cleared in Q3 2023. Present at AD/PD 2024. 12/17/24- First patient dosed. 5/9/25- New PET scan data reported. 12/17/25:- First patient dosed; interim Phase 2 data in 2026.
Verification
Confirm timing and program details against the company announcement or filing.